Tokyo Tape
Sign in
← Kaken Pharmaceutical

Quarterly report · Q3

4521.TEDINET S100Q58K
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥55.6bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥76.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥57.7bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥12.4bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥13.9bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥13.0bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥17.5bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥14.3bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥12.6bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥14.5bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥9.1bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥9.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥10.2bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥9.1bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥10.2bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥167.8bnat 2022-12-31Cons.Assets
Total assets¥165.2bnat 2022-03-31Cons.Assets
Total assets¥169.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥27.1bnat 2022-12-31Cons.Liabilities
Total liabilities¥26.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥140.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥138.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥139.7bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥55.9bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥61.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥243.312022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥84.992022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥251.432021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥269.412021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥93.22021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio83.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio83.4%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio81.9%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q3r_E00935-000Medicinereportable segmentrevenue2022-04-01 → 2022-12-31¥53.8bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentrevenue external2022-04-01 → 2022-12-31¥53.8bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentsegment profit2022-04-01 → 2022-12-31¥11.4bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentrevenue2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentrevenue external2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentsegment profit2022-04-01 → 2022-12-31¥960m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥55.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥55.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥12.4bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentrevenue2021-04-01 → 2021-12-31¥55.9bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentrevenue external2021-04-01 → 2021-12-31¥55.9bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentsegment profit2021-04-01 → 2021-12-31¥12.9bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentrevenue2021-04-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentrevenue external2021-04-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentsegment profit2021-04-01 → 2021-12-31¥998m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥57.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥57.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥13.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 381
ItemContextValueUnit
Salaries sgaPrior1YTDDuration4287000000JPY
Salaries sgaCurrentYTDDuration4211000000JPY
Bonuses and provision for bonuses sgaPrior1YTDDuration966000000JPY
Bonuses and provision for bonuses sgaCurrentYTDDuration909000000JPY
Retirement benefit expenses sgaPrior1YTDDuration281000000JPY
Retirement benefit expenses sgaCurrentYTDDuration256000000JPY
Research and development expenses sgaPrior1YTDDuration6035000000JPY
Research and development expenses sgaCurrentYTDDuration6310000000JPY
Other sgaPrior1YTDDuration6559000000JPY
Other sgaCurrentYTDDuration6480000000JPY
Selling general and administrative expensesPrior1YTDDuration18129000000JPY
Selling general and administrative expensesCurrentYTDDuration18168000000JPY
Operating incomePrior1YTDDuration13889000000JPY
Operating incomeCurrentYTDDuration12394000000JPY
Interest income noiPrior1YTDDuration5000000JPY
Interest income noiCurrentYTDDuration5000000JPY
Dividends income noiPrior1YTDDuration387000000JPY
Dividends income noiCurrentYTDDuration428000000JPY
Subsidy income noiPrior1YTDDuration－JPY
Subsidy income noiCurrentYTDDuration114000000JPY
Other noiPrior1YTDDuration84000000JPY
Other noiCurrentYTDDuration52000000JPY
Non operating incomePrior1YTDDuration477000000JPY
Non operating incomeCurrentYTDDuration600000000JPY
Interest expenses noePrior1YTDDuration12000000JPY
Interest expenses noeCurrentYTDDuration12000000JPY
Foreign exchange losses noePrior1YTDDuration20000000JPY
Foreign exchange losses noeCurrentYTDDuration1000000JPY
Other noePrior1YTDDuration11000000JPY
Other noeCurrentYTDDuration4000000JPY
Non operating expensesPrior1YTDDuration44000000JPY
Non operating expensesCurrentYTDDuration18000000JPY
Ordinary incomePrior1YTDDuration14322000000JPY
Ordinary incomeCurrentYTDDuration12976000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration195000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration2000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration1000000JPY
Extraordinary incomePrior1YTDDuration195000000JPY
Extraordinary incomeCurrentYTDDuration4000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration60000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration34000000JPY
Impairment loss elPrior1YTDDuration－JPY
Impairment loss elCurrentYTDDuration304000000JPY
Extraordinary lossPrior1YTDDuration60000000JPY
Extraordinary lossCurrentYTDDuration338000000JPY
Income before income taxesPrior1YTDDuration14457000000JPY
Income before income taxesCurrentYTDDuration12641000000JPY
Income taxesPrior1YTDDuration4211000000JPY
Income taxesCurrentYTDDuration3492000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass